Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context

Summary: Background: We previously demonstrated the safety and immunogenicity of an MF59-adjuvanted COVID-19 vaccine based on the SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a molecular clamp using HIV-1 glycoprotein 41 sequences. Here, we describe 12-month results in a...

Celý popis

Podrobná bibliografie
Hlavní autoři: Keith J. Chappell, Francesca L. Mordant, Alberto A. Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Danushka K. Wijesundara, Julia A. Lackenby, Paul Griffin, Jillian K. Bennet, Luca Hensen, Wuji Zhang, Thi H.O. Nguyen, Mai H. Tran, Peter Tapley, James Barnes, Patrick C. Reading, Katherine Kedzierska, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro
Médium: Článek
Jazyk:English
Vydáno: Elsevier 2023-11-01
Edice:EBioMedicine
Témata:
Clinical trial
Phase 1
COVID-19 vaccine
Severe acute respiratory syndrome coronavirus 2
Spike protein
SARS-CoV-2
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2352396423004085

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423004085

Podobné jednotky